Shanghai Yingli Pharmaceutical Co. Ltd. has discovered hydrazine-structured compounds as inhibitors of GTPase KRAS and its mutants. They are reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results